Payment overview · 2025
General Payments
$1,063.83
48 reported records · 11 companies
Healthcare provider profile · identity verified
James R Bledsoe, PA
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant|Medical · CORRIGAN, TX · NPI 1508902321
Verified facts
What the public records show
CMS Open Payments records show James R Bledsoe, PA received $1,063.83 in general payments during 2025 across 48 reported records.
AstraZeneca Pharmaceuticals LP accounted for 34.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 107 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 194 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $363.44 | 34.2% | 17 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $169.21 | 15.9% | 10 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $157.15 | 14.8% | 8 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $115.07 | 10.8% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $85.53 | 8.0% | 4 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $57.89 | 5.4% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $39.19 | 3.7% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $25.11 | 2.4% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.06 | 1.8% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $16.93 | 1.6% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.25 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,063.83 | 48 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $169.21 | 10 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $157.15 | 8 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $138.84 | 6 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $131.81 | 7 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $127.10 | 5 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $121.49 | 8 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $115.07 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $85.53 | 4 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $57.89 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $39.19 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $31.19 | 2 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $25.11 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $20.40 | 1 | 2025 |
Source payment records
|
|||||
| KEVEYIS Normalized: keveyis |
Drug | Xeris Pharmaceuticals, Inc. | $19.06 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $16.93 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $15.25 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 194 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 48 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
48 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
107 | 24 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
194 | 42 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 360 | 111 |
| Levothyroxine Sodium | Levothyroxine Sodium | 286 | 87 |
| Furosemide | Furosemide | 269 | 84 |
| Amlodipine Besylate | Amlodipine Besylate | 239 | 78 |
| Lisinopril | Lisinopril | 230 | 69 |
| Prednisone | Prednisone | 211 | 109 |
| Ozempic | Semaglutide | 194 | 42 |
| Omeprazole | Omeprazole | 187 | 55 |
| Losartan Potassium | Losartan Potassium | 179 | 63 |
| Metformin Hcl | Metformin Hcl | 170 | 49 |
| Azithromycin | Azithromycin | 169 | 101 |
| Tramadol Hcl | Tramadol Hcl | 159 | 44 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 156 | 51 |
| Gabapentin | Gabapentin | 151 | 50 |
| Pregabalin | Pregabalin | 132 | 38 |
| Montelukast Sodium | Montelukast Sodium | 129 | 29 |
| Tamsulosin Hcl | Tamsulosin Hcl | 123 | 31 |
| Carvedilol | Carvedilol | 116 | 42 |
| Pantoprazole Sodium | Pantoprazole Sodium | 112 | 41 |
| Meloxicam | Meloxicam | 108 | 44 |
| Clopidogrel | Clopidogrel Bisulfate | 107 | 35 |
| Hydrochlorothiazide | Hydrochlorothiazide | 107 | 31 |
| Mounjaro | Tirzepatide | 107 | 24 |
| Alprazolam | Alprazolam | 105 | 22 |
| Potassium Chloride | Potassium Chloride | 103 | 36 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 102 | 27 |
| Fluticasone Propionate | Fluticasone Propionate | 99 | 25 |
| Metoprolol Tartrate | Metoprolol Tartrate | 99 | 27 |
| Zolpidem Tartrate | Zolpidem Tartrate | 98 | 20 |
| Allopurinol | Allopurinol | 96 | 31 |
| Spironolactone | Spironolactone | 95 | 34 |
| Dicyclomine Hcl | Dicyclomine Hcl | 92 | 27 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 91 | 41 |
| Testosterone Cypionate | Testosterone Cypionate | 91 | 30 |
| Trazodone Hcl | Trazodone Hcl | 89 | 29 |
| Lorazepam | Lorazepam | 87 | 27 |
| Clonazepam | Clonazepam | 85 | 23 |
| Fenofibrate | Fenofibrate Nanocrystallized | 83 | 18 |
| Simvastatin | Simvastatin | 83 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 82 | 26 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 81 | 30 |
| Metoprolol Succinate | Metoprolol Succinate | 80 | 35 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 77 | 49 |
| Methylprednisolone | Methylprednisolone | 77 | 52 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 71 | 20 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 66 | 41 |
| Bupropion Hcl Sr | Bupropion Hcl | 64 | 19 |
| Levofloxacin | Levofloxacin | 61 | 37 |
| Clonidine Hcl | Clonidine Hcl | 60 | 26 |
| Temazepam | Temazepam | 59 | 17 |
| Pioglitazone Hcl | Pioglitazone Hcl | 57 | 23 |
| Famotidine | Famotidine | 56 | 16 |
| Glimepiride | Glimepiride | 56 | 15 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 53 | 26 |
| Donepezil Hcl | Donepezil Hcl | 51 | 21 |
| Tresiba Flextouch U-200 | Insulin Degludec | 50 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 49 | 25 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 48 | 21 |
| Eliquis | Apixaban | 47 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 47 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 45 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 44 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 42 | suppressed |
| Linzess | Linaclotide | 40 | suppressed |
| Nystatin | Nystatin | 38 | 25 |
| Topiramate | Topiramate | 36 | 14 |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 35 | 26 |
| Buspirone Hcl | Buspirone Hcl | 34 | suppressed |
| Celecoxib | Celecoxib | 34 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 34 | 12 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 33 | 15 |
| Memantine Hcl | Memantine Hcl | 31 | 11 |
| Nitroglycerin | Nitroglycerin | 31 | 22 |
| Paroxetine Hcl | Paroxetine Hcl | 31 | 12 |
| Colestipol Hcl | Colestipol Hcl | 30 | 12 |
| Metronidazole | Metronidazole | 30 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 28 | 14 |
| Fluconazole | Fluconazole | 28 | 16 |
| Sertraline Hcl | Sertraline Hcl | 28 | 12 |
| Ketoconazole | Ketoconazole | 27 | 13 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 27 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 27 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 27 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 27 | suppressed |
| Carisoprodol | Carisoprodol | 26 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 26 | 16 |
| Progesterone | Progesterone, Micronized | 26 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 25 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 25 | suppressed |
| Mirtazapine | Mirtazapine | 25 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 24 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 24 | suppressed |
| Methocarbamol | Methocarbamol | 24 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 24 | 15 |
| Sumatriptan Succinate | Sumatriptan Succinate | 24 | 13 |
| Clobetasol Propionate | Clobetasol Propionate | 23 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 23 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 23 | suppressed |
| Nifedipine Er | Nifedipine | 22 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 22 | 11 |
| Warfarin Sodium | Warfarin Sodium | 22 | suppressed |
| Ezetimibe | Ezetimibe | 21 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 21 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 20 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 20 | suppressed |
| Diazepam | Diazepam | 20 | suppressed |
| Finasteride | Finasteride | 20 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 20 | suppressed |
| Modafinil | Modafinil | 20 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 15 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 19 | suppressed |
| Cilostazol | Cilostazol | 19 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 19 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 19 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 19 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 19 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 18 | 11 |
| Divalproex Sodium | Divalproex Sodium | 18 | suppressed |
| Folic Acid | Folic Acid | 18 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl/Pf | 18 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 18 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | suppressed |
| Xarelto | Rivaroxaban | 18 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 17 | 12 |
| Valacyclovir | Valacyclovir Hcl | 17 | suppressed |
| Acyclovir | Acyclovir | 16 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 16 | suppressed |
| Lamotrigine | Lamotrigine | 16 | suppressed |
| Nyamyc | Nystatin | 16 | 11 |
| Portia | Levonorgestrel/Ethin.Estradiol | 16 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 15 | suppressed |
| Dutasteride | Dutasteride | 15 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 15 | suppressed |
| Baclofen | Baclofen | 14 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 14 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 14 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 14 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 14 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 14 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Lactulose | Lactulose | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Penicillin V Potassium | Penicillin V Potassium | 13 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Synthroid | Levothyroxine Sodium | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Aviane | Levonorgestrel/Ethin.Estradiol | 12 | suppressed |
| Cefdinir | Cefdinir | 12 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 12 | suppressed |
| Invokana | Canagliflozin | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 11 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Ertapenem | Ertapenem Sodium | 11 | suppressed |
| Eszopiclone | Eszopiclone | 11 | suppressed |
| Glipizide | Glipizide | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Linezolid | Linezolid | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,063.83 · 48 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AREXVY, BREZTRI, Cologuard Collection Kit, FARXIGA, INSPIRE, JARDIANCE, KEVEYIS, Kerendia, Ozempic, QULIPTA, Rybelsus, Sunosi, TRELEGY ELLIPTA, UBRELVY, Veozah | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error